Brimonidine Tartrate is the tartrate salt form of brimonidine, an imidazole derivative and a selective alpha-2 adrenergic receptor agonist. Upon ocular administration, brimonidine tartrate acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor. Brimonidine tartrate also enhances the outflow of aqueous humor. This drug is used to treat glaucoma to reduce intraocular pressure. It is grouped under the following drug class(es): Alpha-2 agonists. Its therapeutic use is listed as dermatologicals and ophthalmic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Alphagan, Qoliana and Lumify. Its PubChem CID is 54405.
Brimonidine tartrate
| CAS No | 70359-46-5 |
|---|---|
| Molecular Formula | C15H16BrN5O6 |
| Molecular Weight | 442.22 g/mol |
| Synonyms | 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;(2R,3R)-2,3-dihydroxybutanedioic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Brimonidine Tartrate is the tartrate salt form of brimonidine, an imidazole derivative and a selective alpha-2 adrenergic receptor agonist. Upon ocular administration, brimonidine tartrate acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor.
The listed CAS number is 70359-46-5.
The listed molecular formula is C15H16BrN5O6.
The listed molecular weight is 442.22 g/mol.
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;(2R,3R)-2,3-dihydroxybutanedioic acid.
The source lists Alphagan, Qoliana and Lumify.